In early disease, TDLN- is essential for immunotherapeutic response and antitumor immune activation, but TDLN+ is not necessary for immunotherapeutic response in advanced disease; tumor antigen-specific CD8+ T cells are not able to survive in the TDLN+ microenvironment. This evidence concerns the gene CD8A and neoplasm.